RxDoctor Payments Data

Kelly Tolar

Physician Assistant · Keller, TXNPI 1326260472

Payments from drug & device makers

$9,154in general payments, 2019–2025

Across 294 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • AbbVie$832
  • AstraZeneca$717
  • Novo Nordisk$606
  • Pfizer$538
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$8009%
  • Travel & lodging$1,45616%
  • Food & beverage$6,83375%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,154 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$28,343
Medicare patients
116
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate24$21,027
FarxigaDapagliflozin Propanediol12$12,593
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,287
SynthroidLevothyroxine Sodium21$1,173
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,020
Atorvastatin Calcium71$1,007
Rosuvastatin Calcium58$987
Celecoxib26$653
Solifenacin Succinate16$615
Levothyroxine Sodium51$592
Losartan Potassium24$516
Olmesartan Medoxomil29$470
Omeprazole14$392
Tramadol Hcl25$389
Ezetimibe14$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$251$21,02724 claims
AstraZenecaFarxiga$717$12,59312 claims
AbbVieSynthroid$832$1,17321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Keller

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →